|1.||Zamvil, Scott S: 2 articles (08/2014 - 01/2013)|
|2.||Weber, Martin S: 2 articles (08/2014 - 01/2013)|
|3.||Gannon, Philippe O: 1 article (07/2015)|
|4.||Allard, Mathilde: 1 article (07/2015)|
|5.||Baumgaertner, Petra: 1 article (07/2015)|
|6.||Wieckowski, Sébastien: 1 article (07/2015)|
|7.||Speiser, Daniel E: 1 article (07/2015)|
|8.||Hebeisen, Michaël: 1 article (07/2015)|
|9.||Rufer, Nathalie: 1 article (07/2015)|
|10.||Takeda, Atsuhito: 1 article (03/2015)|
03/01/2015 - "The serum concentration of procollagen type III amino-terminal peptide (P-III-P), a biomarker for myocardial fibrosis, in group A was compared with the concentration in group B. "
01/01/1992 - "The serum levels of total bile acid (TBA) and procollagen-III-peptide (P-III-P) correlated well with the development of hepatic fibrosis and the portal hypertension. "
01/01/1992 - "Among various hematologic and biochemical serum indicators of liver damage, the serum levels of total bile acid (TBA) and procollagen-III-peptide (P-III-P) strongly correlated with the development of hepatic fibrosis and protal hypertension. "
12/01/1989 - "Increased levels of serum procollagen III peptide (P-III-P) have been found in patients with alcoholic hepatitis and cirrhosis. "
11/15/2004 - "Significant improvement in serum markers of hepatic fibrosis such as hyaluronic acid (HA) and type III procollagenic peptide (P III P) in group A was seen (P<0.05). "
07/01/2015 - "Our strategy was successful in demonstrating that the type of peptide impacted on TCR/CD8:pMHC avidity, as tumor-reactive T cell clones derived from patients vaccinated with the low-affinity (native) peptide expressed slower koff rates than those derived from patients vaccinated with the high-affinity (analog) peptide (p < 0.0001). "
01/07/2005 - "Inbred mice (FVB/n) vaccinated with the disulfide-paired epitope exhibited a statistically significant reduction in the development of exogenously administered tumors in vivo compared with mice receiving either the free uncyclized or the promiscuous T-cell epitope (MVF) control peptide (p = 0.001). "
12/19/2012 - "In addition, tumor uptake was significantly blocked by coinjection of excess NDP-α-MSH peptide (p < 0.05). "
06/01/2007 - "Furthermore, the B16/F10 tumor uptake was significantly inhibited by coinjection with excess alpha-MSH peptide (P < 0.05), indicating that (18)F-FB-NAPamide specifically recognizes the MC1R in living mice. "
05/20/1989 - "Usefulness of type III procollagen peptide (P-III-P) in sera as tumor marker was investigated in patients with ovarian tumors. "
|3.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
03/01/1972 - "A major disease-inducing site for induction of experimental allergic encephalomyelitis in monkeys exists in Peptide P 14, the 37-residue segment of the A1 protein comprising its COOH-terminus. "
01/01/2013 - "C57BL/6 mice younger than eight weeks were resistant to experimental autoimmune encephalomyelitis (EAE) following active immunization with myelin oligodendrocyte glycoprotein (MOG) peptide (p) 35-55. "
12/01/1999 - "Immunization of C57BL / 6 mice with myelin oligodendrocyte glycoprotein (MOG) peptide (p) 35 - 55 induces chronic experimental autoimmune encephalomyelitis (EAE). "
08/01/2014 - "Studies evaluating T-cell recognition of myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis (MS) and its model, experimental autoimmune encephalomyelitis (EAE), have focused mostly on its 117 amino acid (aa) extracellular domain, especially peptide (p) 35-55. "
|1.||Hyaluronic Acid (Hyaluronan)
|2.||T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)
|3.||Biological Markers (Surrogate Marker)
|6.||Collagen Type III (Type III Collagen)
|8.||Collagen Type IV (Type IV Collagen)